Concepedia

Author

Ted Vandenberg

BC Cancer Agency

Also Known As

T A Vandenberg, T Vandenberg, T. A. Vandenberg, T. Vandenberg, T.A. Vandenberg, Ted A. Vandenberg, Ted Vandenberg

47

Publications

3.9K

Citations

22

H-Index

28

Concepts

All Affiliations

BC Cancer AgencyLondon Health Sciences CentreSunnybrook Health Science CentreMcMaster UniversityJuravinski Cancer Centre
TV

About

Ted Vandenberg is an author at BC Cancer Agency specializing in oncology, breast cancer, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

10

10

530

2

Health Sciences

5

5

268

3

Obstetrics

4

4

103

4

Nursing

1

1

29

5

Immunology

1

1

46

Ted Vandenberg

×

26

Publications

3.6K

Citations

21

H-Index

YearCitations

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André,

Annals of Oncology

2021

689

Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.

Mark N. Levine, V. Bramwell, Kathleen I. Pritchard,

Journal of Clinical Oncology

1998

622

Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing Chemotherapy

Jean‐Marc Nabholtz, H.-J. Senn, W.R. Bezwoda,

Journal of Clinical Oncology

1999

506

Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer

Rita S. Mehta, William E. Barlow, Kathy S. Albain,

New England Journal of Medicine

2012

373

Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163

Susan Ellard, Mark Clemons, Karen A. Gelmon,

Journal of Clinical Oncology

2009

260

Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer

Margot J. Burnell, Mark N. Levine, Judith‐Anne W. Chapman,

Journal of Clinical Oncology

2009

152

Phase III Comparative Study of Vinorelbine Combined With Doxorubicin Versus Doxorubicin Alone in Disseminated Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8

B. Norris, Kathleen I. Pritchard, K. James,

Journal of Clinical Oncology

2000

143

Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer

Rita S. Mehta, William E. Barlow, Kathy S. Albain,

New England Journal of Medicine

2019

125

Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres.

B O’Brien, James J. Rusthoven, A. Rocchi,

PubMed

1993

90

Randomized Trial of Tamoxifen Versus Combined Tamoxifen and Octreotide LAR Therapy in the Adjuvant Treatment of Early-Stage Breast Cancer in Postmenopausal Women: NCIC CTG MA.14

Kathleen I. Pritchard, Lois E. Shepherd, Judith‐Anne W. Chapman,

Journal of Clinical Oncology

2011

85

Page 1